PRE News and Press, Prenetics Global Limited From 09/15/23

2023-09-15 14:47:14 ET More on Prenetics Global Seeking Alpha’s Quant Rating on Prenetics Global Historical earnings data for Prenetics Global Financial information for Prenetics Global For further details see: Prenetics Global GAAP EPS of -$0.14, ...

World Copper (WCUFF) is expected to report $-0.01 for Q2 2023 GlassBridge Enterprises Inc (GLAE) is expected to report for quarter end 2023-06-30 Paladin Energy Ltd (PALAF) is expected to report for Q4 2023 Andritz AG ADR (ADRZY) is expected to report for Q2 2023 Cincinnati Bancor...

HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent busin...

Anebulo Pharmaceuticals Inc. (ANEB) is expected to report for Q4 2023 Minera IRL Ltd ADR (MRLLY) is expected to report for Q3 2023 OpenLocker Holdings Inc (OLKR) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-0.43 for Q2 2024 Sompo Holdings I...

Prenetics Global Limited (PRE) is expected to report for Q2 2023

(NewsDirect) Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its f...

(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission...

2023-06-05 07:34:18 ET Prenetics Global press release ( NASDAQ: PRE ): Q1 GAAP EPS of -$0.07. Revenue of $17.7M (-80.8% Y/Y). For further details see: Prenetics Global GAAP EPS of -$0.07, revenue of $17.7M

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent busine...

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology LONDON AND HONG KONG, Mar 14, 2023 - (ACN Newswire) - Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision ...